---
title: "GIANT BIOGENE's collagen facial injection product has received the registration certificate from the drug regulatory authority"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/262344381.md"
description: "GIANT BIOGENE announced that its wholly-owned subsidiary, Shaanxi GIANT BIOGENE, has obtained the medical device registration certificate issued by the National Medical Products Administration, approving its recombinant type I α1 subtype collagen freeze-dried fiber product for facial dermal tissue filling to correct dynamic wrinkles on the forehead. This is the first recombinant type I natural sequence collagen facial injectable product in China"
datetime: "2025-10-23T04:09:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262344381.md)
  - [en](https://longbridge.com/en/news/262344381.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262344381.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/262344381.md) | [繁體中文](https://longbridge.com/zh-HK/news/262344381.md)


# GIANT BIOGENE's collagen facial injection product has received the registration certificate from the drug regulatory authority

GIANT BIOGENE (02367.HK) announced that its wholly-owned subsidiary, Shaanxi GIANT BIOGENE, has today received the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration for its recombinant type I α1 collagen freeze-dried fiber product. This product, which uses recombinant collagen as the main ingredient, is intended for facial dermal tissue filling to correct dynamic wrinkles in the forehead, including glabellar lines, forehead lines, and crow's feet.

The company stated that this product is China's first recombinant type I natural sequence collagen facial injectable product, officially approved through a joint review by the device and drug regulatory authorities

### 相关股票

- [GIANT BIOGENE (02367.HK)](https://longbridge.com/zh-CN/quote/02367.HK.md)

## 相关资讯与研究

- [PetroChina Renews Financial Deal With Related Company](https://longbridge.com/zh-CN/news/280998322.md)
- [EPC Space adds EPC7C010 and EPC7C011 half-bridge buck platforms for high-rel and rad-hard applications](https://longbridge.com/zh-CN/news/281400207.md)
- [Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe](https://longbridge.com/zh-CN/news/280997570.md)
- [Samsung Biologics labor union members have overwhelmingly voted in favor of strike, with 95.52% voting in favor on 95.38% turnout](https://longbridge.com/zh-CN/news/281030155.md)
- [Getech Wins Three-Year Globe Platform Renewal With Asian Oil Producer](https://longbridge.com/zh-CN/news/281133108.md)